Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Auto-generated profile, based on publicly available information
Bo Zhang
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
First-line systemic therapeutic options for advanced esophageal squamous cell carcinoma (ESCC) are limited. In this multicenter, double-blind phase 3 trial, a total of 551 patients with previously untreated, locally advanced or metastatic ESCC and PD-L1 combined positive score of ≥1 were randomized (2:1) to receive serplulimab (an anti-PD-1 antibody; 3 mg/kg) or placebo (on day 1), plus cisplatin (50 mg/m2) (on day 1) and continuous infusion of 5-fluorouracil (1,200 mg/m2) (on days 1 and 2), once every 2 weeks. The study met the primary endpoints. At the prespecified final analysis of progression-free survival (PFS) assessed by the blinded independent radiological review committee, serplulimab plus chemotherapy significantly improved PFS compared with placebo plus chemotherapy (median PFS of 5.8 months and 5.3 months, respectively; hazard ratio, 0.60; 95% confidence interval, 0.48–0.75; P < 0.0001). At the prespecified interim analysis of overall survival (OS), serplulimab plus chemotherapy also significantly prolonged OS compared with placebo plus chemotherapy (median OS of 15.3 months and 11.8 months, respectively; hazard ratio, 0.68; 95% confidence interval, 0.53–0.87; P = 0.0020). Grade 3 or higher treatment-related adverse events occurred in 201 (53%) and 81 (48%) patients in the serplulimab plus chemotherapy group and the placebo plus chemotherapy group, respectively. Serplulimab plus chemotherapy administered every 2 weeks significantly improved PFS and OS in patients with previously untreated, PD-L1-positive advanced ESCC, with a manageable safety profile. This study is registered with ClinicalTrials.gov (NCT03958890).
1 October 2013 in Journal of Traditional Chinese Medicine
Objective: To compare the curative effects of heat-sensitive moxibustion with conventional drugs on chronic persistent asthma and seek a valuable therapy to replace Western Medicine. Methods: The participants in this multi-center, randomized, and controlled study were randomly divided into two groups: group A (n=144), treated with heat-sensitive moxibustion (50 sessions) and group B (n=144), treated with Seretide (salmeterol 50 µg/fluticasone 250 µg, twice a day). The scores of asthma control test (ACT), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), and attack frequency were measured after 15, 30, 60, and 90 days of treatment. Patients followed up 3 and 6 months after treatment. Results: There was a significant difference (P= 0.0002) in the ACT score and lung function between the two groups after 3 months of treatment and (P=0.000 03) during the follow-up visits. In addition, heat-sensitive moxibustion reduced attack frequency in the period from inclusion to the 6-month follow-up visit. Conclusion: This study shows that heat-sensitive moxibustion may have a comparable curative effect to Seretide(salmeterol/fluticasone) on asthma.
Background: Endovascular aneurysm repair (EVAR) is one of the first-line therapies of abdominal aortic aneurysms. Postoperative endoleak is the most common complication of EVAR. Computed tomography angiography (CTA), which is routine for follow-up, has side effects (e.g., radiation) and also has a certain percentage of missed diagnosis. Preliminary studies on contrast-enhanced ultrasound (CEUS) have shown that the sensitivity of CEUS for detecting endoleak is no lower than that of CTA. To investigate the advantages of CEUS, we conducted CEUS examinations of post-EVAR cases in which CTA failed to detect endoleak or could not verify the type of endoleak. Methods: Post-EVAR patients, who were clinically considered to have endoleak and met the inclusion criteria were enrolled between March 2013 and November 2014. All of the patients underwent color Doppler flow imaging (CDFI) and a CEUS examination. Size, location, microbubble dispersion, and hemodynamic characteristics of leaks were recorded. Comparison between the diagnosis of CEUS and CDFI was conducted using Fisher's exact test and clinical outcomes of all patients were followed up. Results: Sixteen patients were enrolled, and 12 (75%) had endoleaks with verified types by CEUS. Among 12 cases of endoleaks were positive by CEUS, 10 were CDFI-positive, and the four CEUS-negative cases were all negative by CDFI. The diagnostic values of CEUS and CDFI were statistically different (P = 0.008). Six patients with high-pressure endoleaks received endovascular re-intervention guided by CEUS results. One patient with type III endoleak had open surgery when endovascular repair failed. Conclusions: CEUS is a new, safe, and effective means for detection of endoleaks post-EVAR. This technique can be used as a supplement for routine CTA follow-up to provide more detailed information on endoleak and its category.
Background: Generative artificial intelligence (GenAI) models are increasingly used for medical information retrieval, due to their accessibility and efficiency. However, the accuracy and readability of their responses, specifically for upper gastrointestinal cancers, remain inadequately evaluated. This gap highlights the need for rigorous assessment to ensure reliable patient education and clinical integration. Objective: This study aimed to assess the accuracy and readability of responses generated by four prominent GenAI models (Kimi, DeepSeek, ChatGPT, and Gemini) when addressing patient-focused questions related to esophageal and gastric cancers. Methods: Twenty-five standardized medical questions about esophageal and gastric cancer covering domains of disease definition, treatment and management were posed to each model. Responses were assessed by four oncologists for accuracy by a 5-point Likert scale and analyzed for readability using Flesch–Kincaid Reading Ease, Flesch–Kincaid Grade Level, and SMOG metrics. High-interest questions for patients were identified via questionnaires. Results: Comparing the accuracy of GenAI-generated responses, DeepSeek achieved the highest overall accuracy score and outperformed other models in questions about definitions and treatments, while ChatGPT excelled in management-related inquiries. In subgroup analysis, GenAI models exhibited higher accuracy in answering definition and management questions, which patients preferred to inquire, compared with questions about cancer therapies. The responses produced by all models required a reading capacity from 11th-grade to college level. Conclusions: This study revealed that in this comparative evaluation application of GenAI models, DeepSeek provides the most accurate responses for upper GI cancer inquiries about definition and treatment, while ChatGPT showed superiority in management-related questions. However, all models generate texts requiring advanced reading levels, highlighting a need for readability optimization without compromising accuracy. GenAI shows promise for patient education but requires rigorous validation for clinical integration.
Background: There are limited reports on nanoparticle albumin bound‐paclitaxel (nab‐paclitaxel) regimens as second‐ or third‐line treatments for advanced esophageal squamous cell carcinoma (ESCC). Additionally, its safety and efficacy in ESCC patients after failure of first‐line programmed cell death protein‐1 (PD‐1) blockade plus chemotherapy have not been reported. In this study, we aimed to assess the efficacy and tolerability of nab‐paclitaxel regimens as second‐ or later‐line treatment in advanced ESCC.Methods: We retrospectively reviewed clinical data of advanced ESCC patients who participated in a randomized phase III clinical study and received serplulimab or placebo plus chemotherapy at our institution, and consecutive patients who received subsequent nab‐paclitaxel‐based regimens as second‐ or later‐line treatment were included for data collection and analysis.Results: A total of 39 patients were included, 25 (64.1%) received serplulimab plus chemotherapy and 14 (35.9%) received chemotherapy alone as first‐line treatment. Treatment strategies included nab‐paclitaxel monotherapy (7/39, 17.9%), or in combination with other chemotherapy (19/39, 48.7%), with anti‐PD‐1 antibodies (12/39, 30.8%) or with nimotuzumab (1/39, 2.6%). Overall, the objective response rate (ORR) and disease control rate (DCR) were 33.3% (13/39) and 61.5% (24/39), respectively. With a median follow‐up of 9.7 months, the median progression‐free survival and median overall survival were 5.0 and 7.9 months, respectively. The most common adverse events were neuropathy peripheral (30.8%), anemia (30.8%), neutrophil count decreased (23.1%), and nausea (20.5%).Conclusions: Nab‐paclitaxel‐based regimen could be a safe and effective option as second‐ or later‐line treatment in patients with advanced ESCC, regardless of their previous exposure to PD‐1 inhibitors.
11 August 2023 in Journal of the National Cancer Center
Esophageal cancer (EC) is particularly common in China. With the continuing progress of multi-disciplinary therapy including early screening, minimally invasive techniques, radiotherapy and chemotherapy, the 5-year survival of EC has been improved in China. However, there are considerable disparities in the diagnosis and treatment quality among different regions. The Esophageal Cancer Expert Committee of the National Cancer Quality Control Center (NCQCC) considers a set of authoritative quality control standards as an opportunity to eliminate the disparities and improve the overall survival and quality of life of EC. To further promote the quality control for standardized diagnosis and treatment of EC, the National Cancer Center commissioned the Esophageal Cancer Quality Control Expert Committee to draft and formulate the Chinese Quality Control Indices for Standardized Diagnosis and Treatment of Esophageal Cancer (2022 edition). The Indices includes 21 items that cover all key areas in the diagnosis and treatment of esophageal cancer, such as medical oncology, radiation oncology, endoscopy, and pathology.